COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00110266
Recruitment Status : Completed
First Posted : May 5, 2005
Last Update Posted : November 18, 2016
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
The purpose of this trial is to examine the safety and efficacy of deferasirox in patients with Myelodysplastic Syndrome (MDS) and chronic iron overload from blood transfusions.

Condition or disease Intervention/treatment Phase
Myelodysplastic Syndrome Iron Overload Drug: Deferasirox Phase 2

Detailed Description:
Study entry requires a diagnosis of low or intermediate (INT-1) risk MDS per International Prognostic Scoring System (IPSS) criteria and serum ferritin ≥ 1000 ng/mL. Patients must have had at least 30 prior red blood cell transfusions. Deferasirox will be administered at an initial dose of 20 mg/kg orally once per day. Patient transfusion history and at least three complete blood count (CBC) values must be available for the 12 weeks prior to study registration for patients with MDS and chronic iron overload from blood transfusions.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 176 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Safety and Tolerability Study of Deferasirox for Treatment of Transfusional Iron Overload in Low-risk and INT-1, Myelodysplastic Patients Using Serum Ferritin Monitoring
Study Start Date : May 2005
Actual Primary Completion Date : March 2010
Actual Study Completion Date : March 2010

Arm Intervention/treatment
Experimental: ICL670
Evaluate the safety and tolerability of deferasirox 20 mg/kg/day over one year in patients with MDS
Drug: Deferasirox
20 mg/kg/day over one year in patients with MDS
Other Names:
  • ICL670A
  • chelator
  • desferal
  • iron chelation

Primary Outcome Measures :
  1. 12 month safety in patients with myelodysplastic syndrome (MDS) [ Time Frame: throughout the study ]

Secondary Outcome Measures :
  1. Changes in serum ferritin from baseline to 3, 6, 9 and 12 months after initiating treatment [ Time Frame: throughout the study ]
  2. Effect of non-transferrin bound iron (NTBI), serum iron, transferrin and transferrin saturation on the safe administration of deferasirox [ Time Frame: throughout the study ]
  3. Changes in transfusion requirements, serum erythropoietin levels, and estimated frequency of hematologic improvement in patients who are not receiving growth factors or chemotherapy for their underlying MDS. [ Time Frame: throughout the study ]
  4. Trough pharmacokinetic parameters of deferasirox in patients with MDS [ Time Frame: throughout the study ]
  5. Drug accountability [ Time Frame: through out the study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female patients with low or intermediate (INT-1) risk MDS
  • Patients can be EITHER naïve to iron chelation OR have had prior treatment with deferoxamine (DFO).
  • Age greater than or equal to 18 years
  • Availability of transfusion records for the 12 weeks prior to registration
  • A lifetime minimum of 30 previous packed red blood cell transfusions
  • Availability of at least three CBC values (pretransfusion) during the 12 weeks prior to registration
  • Serum Ferritin:

For entry into the screening period, serum ferritin ≥ 1000 ng/mL on at least two occasions, at least two weeks apart, during the prior year.

Serum ferritin ≥ 1000 ng/mL at screening via the central lab.

  • Life expectancy ≥ 6 months
  • Sexually active women must use an effective method of contraception, or must have undergone clinically documented total hysterectomy and/or oophorectomy, or tubal ligation or be postmenopausal (defined as amenorrhea for at least 12 months)
  • Able to provide written informed consent

Exclusion Criteria:

  • Serum creatinine above the upper limit of normal
  • ALT > 500 U/L during screening
  • Clinical or laboratory evidence of active Hepatitis B or C
  • Urinary protein/creatinine ratio > 0.5 mg/mg
  • History of HIV positive test result (ELISA or Western blot)
  • ECOG Performance Status > 2
  • Patients with uncontrolled systemic hypertension
  • Unstable cardiac disease not controlled by standard medical therapy
  • Patients with a diagnosis of or history of clinically relevant ocular toxicity related to iron chelation
  • Systemic diseases (cardiovascular, renal, hepatic, etc.) which would prevent study treatment
  • Pregnancy or breast feeding
  • Treatment with systemic investigational drug within the past 4 weeks or topical investigational drug within the past 7 days
  • Other surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of study drug
  • History of non-compliance to medical regimens or patients who are considered potentially unreliable and/or not cooperative

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00110266

Show Show 48 study locations
Sponsors and Collaborators
Novartis Pharmaceuticals
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Additional Information:
Publications of Results:
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals Identifier: NCT00110266    
Obsolete Identifiers: NCT00343837
Other Study ID Numbers: CICL670AUS03
First Posted: May 5, 2005    Key Record Dates
Last Update Posted: November 18, 2016
Last Verified: November 2016
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Iron chelation
Additional relevant MeSH terms:
Layout table for MeSH terms
Myelodysplastic Syndromes
Iron Overload
Bone Marrow Diseases
Hematologic Diseases
Iron Metabolism Disorders
Metabolic Diseases
Iron Chelating Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action